Lv1
46 积分 2024-07-31 加入
Macrophages: Targets for next-generation cancer immunotherapy
13天前
已完结
Low-dose belimumab reduced risk of flares in patients with systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial
6个月前
已完结
ECM1 attenuates hepatic fibrosis by interfering with mediators of latent TGF-β1 activation
7个月前
已完结
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
8个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
8个月前
已完结
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
8个月前
已完结
皖公网安备34019202002308
